
Cat. #156564
Anti-CD8 alpha chain [OX8]
Cat. #: 156564
Unit size: 100 ug
Availability: 10-12 weeks
Target: CD8 alpha chain
Class: Monoclonal
Application: FACS ; IHC
Reactivity: Rat
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Medical Research Council; University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CD8 alpha chain [OX8]
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Rat
- Host: Mouse
- Application: FACS ; IHC
- Description: The antibody recognises subset of rat peripheral T cells that possess suppresser and cytotoxic activities. antibody labels all peripheral T cells that are unlabelled by W3/25. 90% of thymocytes are labelled by both Antibodies. NK cells express the OX-8 antigen.
- Immunogen: High molecular weight rat thymocyte glycoproteins
- Myeloma used: NS1
- Recommended controls: IgG1
Target Details
- Target: CD8 alpha chain
- Target background: The antibody recognises subset of rat peripheral T cells that possess suppresser and cytotoxic activities. antibody labels all peripheral T cells that are unlabelled by W3/25. 90% of thymocytes are labelled by both Antibodies. NK cells express the OX-8 antigen.
Applications
- Application: FACS ; IHC
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Dry ice
References
- Johnson et al. 1985. EMBO J. 4(10):2539-45. PMID: 3932064.
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)


